Drugs / Zirconium Zr 89-Df-Crefmirlimab
Zirconium Zr 89-Df-Crefmirlimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05371132 | Jun 2022 → Oct 2026 expected | lymphoma, metastatic malignant neoplasm | City of Hope Medical Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zirconium Zr 89-Df-Crefmirlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05371132 ↗ |
| Modality | Diagnostic / imaging agent | “Diagnostic procedures, such as zirconium Zr 89-Df-crefmirlimab positron emission tomography (PET)” NCT05371132 ↗ |
| Route | Intravenous | “zirconium Zr 89-Df-crefmirlimab intravenously (IV)” NCT05371132 ↗ |